Paper Summary
Improving Adoptive Cell Transfer: New Combinations for Greater Efficacy

In a paper published in the journal Nature Communications, Parisi et al. from the University of California, Los Angeles described how the novel agonist NKTR-214 outperforms IL-2 for improving ACT anti-tumor efficacy, identifying specific biomarkers that corresponded to increased response using functional proteomics-based cellular characterization.

Download Resource

Your Data is Secure

We will always keep your personal information safe and not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.

In this Paper Summary we discuss:
  • A next-generation agonist for improving persistence and limiting tumor growth
  • Full cellular characterization of immune cells
  • NKTR-214 dramatically increases T cell polyfunctionality, a correlate to persistence

Improving Adoptive Cell Transfer: New Combinations for Greater Efficacy

In a paper published in the journal Nature Communications, Parisi et al. from the University of California, Los Angeles described how the novel agonist NKTR-214 outperforms IL-2 for improving ACT anti-tumor efficacy, identifying specific biomarkers that corresponded to increased response using functional proteomics-based cellular characterization.

IsoPlexis Awards